A pilot study to determine the feasibility of using plasma to detect mutations in patients with Stage II-III NSCLC

A pilot study to determine the feasibility of using plasma to detect mutations in patients with Stage II-III NSCLC
Enrolling By Invitation
18 years - 99 years
All
Phase N/A
150 participants needed
1 Location

Brief description of study

This study will increase our ability to detect mutations in Stage II-III Non Small Cell Lung Cancer patients.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 18 years - 99 years
  • Gender: All


Updated on 04 Aug 2024. Study ID: 848590
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research